Josh Riggs
President and CEO
Replay available
Insight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) Q4 2025 earnings conference call, held 2026-03-26. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Andrea James
Chief Financial Officer
Eki Schutz
Chief Science Officer
Thomas Flatton
Analyst, Lake Street
Mike Mattson
Analyst, Needham
Ben Mee
Analyst, Stevens
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Insight Molecular Diagnostics Inc..
Replay transcript excerpt
WEBVTT 00:00:01.432 -- 00:00:06.980 Welcome, everyone, and thank you for joining us to discuss Inside Molecular Diagnostics' 00:00:06.980 -- 00:00:10.505 fourth quarter 2025 results. 00:00:10.505 -- 00:00:15.953 If you have not seen today's shareholder letter, please visit Inside Molecular Diagnostics' 00:00:15.953 -- 00:00:20.436 investor relations page at investors.imdxinc.com. 00:00:24.765 -- 00:00:30.929 Today's prepared remarks build upon the information already shared in this robust letter. 00:00:30.929 -- 00:00:36.537 Joining us today are Inside Molecular Diagnostics President and CEO Josh Riggs, 00:00:36.537 -- 00:00:42.145 Chief Science Officer Eki Schutz, and CFO Andrea James. 00:00:42.145 -- 00:00:46.110 We also have our analysts with us as panelists. 00:00:46.110 -- 00:00:50.176 After our prepared remarks, our analysts may ask questions. 00:00:50.176 -- 00:00:55.924 Before turning the call over to Josh Riggs, I'd like to go over our safe harbor. 00:00:55.924 -- 00:01:00.848 The company will make projections and forward-looking statements regarding future events. 00:01:00.848 -- 00:01:06.079 Any statements that are not historical facts are forward-looking statements. 00:01:06.079 -- 00:01:11.289 These statements are made pursuant to and within the meaning of the Safe Harbor 00:01:11.289 -- 00:01:17.386 Provision of the Private Securities Litigation Reform Act of 1995. 00:01:17.386 -- 00:01:22.835 We encourage you to review the company's SEC filings, including the company's 00:01:22.835 -- 00:01:27.884 most recent form 10-K and subsequent forms 10-Q, which 00:01:27.884 -- 00:01:33.334 identify risks and uncertainties that may cause future actual results 00:01:33.334 -- 00:01:35.915 or events to differ materially. 00:01:35.915 -- 00:01:41.001 Please note tha...